Table 1.
Reported ADA development for licensed therapeutics.
| Drug name | Type | Clinical use | ADA prevalence | Citation |
|---|---|---|---|---|
| Monoclonal antibodies | ||||
| Muromonab-CD3 | Murine against CD3 | Immunosuppression for the prevention of allograft rejection in transplants | 43–91% | (14–17) |
| Infliximab | Chimeric human/mouse IgG1 against TNFα | Rheumatoid arthritis, inflammatory bowel disease, plaque psoriasis | 5.4–43.6% | (19, 21, 23) |
| Cetuximab | Chimeric human/mouse IgG1 against EGFR | Colorectal cancer, squamous cell carcinoma (head/neck) | 0.6–20.8% | (24) |
| Adalimumab | Human IgG1 against TNFα | Plaque psoriasis, rheumatoid arthritis, Crohn's disease, spondyloarthritis, psoriatic arthritis | 17–49% | (18, 20–22, 25) |
| Other drugs | ||||
| L-Asparaginase | Enzyme | Acute lymphoblastic leukemia in adult and children | 2% (PEG-Asp–neutralizing ADA;) 26% (Escherichia coli-Asp) | (26, 27) |
| FVIII | Anti-hemorrhagic protein | Hemophilia A/B | 3.6–33% (25–30% in those with severe hemophilia) | (28, 29) |
| IFN-β | Mammalian cytokine | Multiple sclerosis | 2–53% | (30–32) |
ADA, antidrug antibody; EGFR, epidermal growth factor receptor.